Curtis Triplitt

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 7

Top Topics

Binding Protein

Chronic Kidney Disease

Angiotensin Converting Enzyme

Top Venues

Diabetes, obesity & metabolism

Clinical diabetes : a publication of the American Diabetes Association

This page only lists publications with an associated author ORCID identifier.

Publications

Carolina Solis-Herrera, Curtis Triplitt
Non-steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes. Diabetes, obesity & metabolism (2023)
Siham Abdelgani, Ahmed Khattab, John Adams, Gozde Baskoy, Curtis Triplitt, Muhammad Abdul-Ghani, Muhammad A Abdul-Ghani
The impact of increased hepatic glucose production caused by empagliflozin on plasma glucose concentration in individuals with type 2 diabetes and nondiabetic individuals. Diabetes, obesity & metabolism 26 (3) (2023)
Carolina Solis-Herrera, Michael P Kane, Curtis Triplitt
Current Understanding of Sodium N-(8-[2-Hydroxylbenzoyl] Amino) Caprylate (SNAC) as an Absorption Enhancer: The Oral Semaglutide Experience. Clinical diabetes : a publication of the American Diabetes Association 42 (1) (2023)
Siham Abdelgani, Ahmed Khattab, John Adams, Gozde Baskoy, Curtis Triplitt, Muhammad Abdul-Ghani, Muhammad A Abdul-Ghani
The impact of increased hepatic glucose production caused by empagliflozin on plasma glucose concentration in individuals with type 2 diabetes and nondiabetic individuals. Diabetes, obesity & metabolism (2023)
Siham Abdelgani, Ahmed Khattab, John Adams, Gozde Baskoy, Curtis Triplitt, Muhammad Abdul-Ghani, Muhammad A Abdul-Ghani
The impact of increased hepatic glucose production caused by empagliflozin on plasma glucose concentration in individuals with type 2 diabetes and nondiabetic individuals. Diabetes, obesity & metabolism 26 (3) (2023)
Siham Abdelgani, Ahmed Khattab, John Adams, Gozde Baskoy, Curtis Triplitt, Muhammad Abdul-Ghani, Muhammad A Abdul-Ghani
The impact of increased hepatic glucose production caused by empagliflozin on plasma glucose concentration in individuals with type 2 diabetes and nondiabetic individuals. Diabetes, obesity & metabolism 26 (3) (2023)
Carolina Solis-Herrera, Michael P Kane, Curtis Triplitt
Current Understanding of Sodium N-(8-[2-Hydroxylbenzoyl] Amino) Caprylate (SNAC) as an Absorption Enhancer: The Oral Semaglutide Experience. Clinical diabetes : a publication of the American Diabetes Association 42 (1) (2023)